336 related articles for article (PubMed ID: 17487473)
1. Comparative CYP-dependent binding of the adrenocortical toxicants 3-methylsulfonyl-DDE and o,p'-DDD in Y-1 adrenal cells.
Hermansson V; Asp V; Bergman A; Bergström U; Brandt I
Arch Toxicol; 2007 Nov; 81(11):793-801. PubMed ID: 17487473
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o,p'-DDD in human adrenal zona fasciculata/reticularis.
Lindhe O; Skogseid B; Brandt I
J Clin Endocrinol Metab; 2002 Mar; 87(3):1319-26. PubMed ID: 11889204
[TBL] [Abstract][Full Text] [Related]
3. Biphasic hormonal responses to the adrenocorticolytic DDT metabolite 3-methylsulfonyl-DDE in human cells.
Asp V; Ullerås E; Lindström V; Bergström U; Oskarsson A; Brandt I
Toxicol Appl Pharmacol; 2010 Feb; 242(3):281-9. PubMed ID: 19900470
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity and decreased corticosterone production in adrenocortical Y-1 cells by 3-methylsulfonyl-DDE and structurally related molecules.
Asp V; Lindström V; Olsson JA; Bergström U; Brandt I
Arch Toxicol; 2009 Apr; 83(4):389-96. PubMed ID: 18651133
[TBL] [Abstract][Full Text] [Related]
5. In vitro bioactivation of the environmental pollutant 3-methylsulphonyl-2, 2-bis(4-chlorophenyl)-1,1-dichloroethene in the human adrenal gland.
Jönsson CJ; Lund BO
Toxicol Lett; 1994 Apr; 71(2):169-75. PubMed ID: 8171446
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of the adrenocorticolytic compounds 3-methylsulphonyl-DDE and o,p'-DDD (mitotane) in Minipigs.
Hermansson V; Cantillana T; Hovander L; Bergman A; Ljungvall K; Magnusson U; Törneke K; Brandt I
Cancer Chemother Pharmacol; 2008 Feb; 61(2):267-74. PubMed ID: 17431626
[TBL] [Abstract][Full Text] [Related]
7. Mitotane effects in a H295R xenograft model of adjuvant treatment of adrenocortical cancer.
Lindhe O; Skogseid B
Horm Metab Res; 2010 Sep; 42(10):725-30. PubMed ID: 20665429
[TBL] [Abstract][Full Text] [Related]
8. DDT- and DDE-induced disruption of ovarian steroidogenesis in prepubertal porcine ovarian follicles: a possible interaction with the main steroidogenic enzymes and estrogen receptor beta.
Wójtowicz AK; Kajta M; Gregoraszczuk EŁ
J Physiol Pharmacol; 2007 Dec; 58(4):873-85. PubMed ID: 18195494
[TBL] [Abstract][Full Text] [Related]
9. Irreversible binding and adrenocorticolytic activity of the DDT metabolite 3-methylsulfonyl-DDE examined in tissue-slice culture.
Lindhe O; Lund BO; Bergman A; Brandt I
Environ Health Perspect; 2001 Feb; 109(2):105-10. PubMed ID: 11266318
[TBL] [Abstract][Full Text] [Related]
10. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
[TBL] [Abstract][Full Text] [Related]
11. Effect of single and repeated in vitro exposure of ovarian follicles to o,p'-DDT and p,p'-DDT and their metabolites.
Wójtowicz AK; Gregoraszczuk EL; Ptak A; Falandysz J
Pol J Pharmacol; 2004; 56(4):465-72. PubMed ID: 15520502
[TBL] [Abstract][Full Text] [Related]
12. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.
Theile D; Haefeli WE; Weiss J
Endocrine; 2015 Aug; 49(3):842-53. PubMed ID: 25542188
[TBL] [Abstract][Full Text] [Related]
13. Treatment with o,p'-DDD (mitotane) decreased cytochrome P-450, heme, and microsomal protein content in the dog adrenal cortex in vivo.
Martz F; Straw JA
Res Commun Chem Pathol Pharmacol; 1976 Jan; 13(1):83-92. PubMed ID: 1257603
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of the organochlorine pesticide DDT and its metabolite p,p'-DDE on p-glycoprotein activity and expression.
Shabbir A; DiStasio S; Zhao J; Cardozo CP; Wolff MS; Caplan AJ
Toxicol Appl Pharmacol; 2005 Mar; 203(2):91-8. PubMed ID: 15710169
[TBL] [Abstract][Full Text] [Related]
15. Anaerobic biodegradation of DDT residues (DDT, DDD, and DDE) in estuarine sediment.
Huang HJ; Liu SM; Kuo CE
J Environ Sci Health B; 2001 May; 36(3):273-88. PubMed ID: 11411851
[TBL] [Abstract][Full Text] [Related]
16. Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.
Kasperlik-Zaluska AA; Cichocki A
J Exp Ther Oncol; 2005; 5(2):125-32. PubMed ID: 16471038
[TBL] [Abstract][Full Text] [Related]
17. Species differences in 3-methylsulphonyl-DDE bioactivation by adrenocortical tissue.
Lindström V; Brandt I; Lindhe O
Arch Toxicol; 2008 Mar; 82(3):159-63. PubMed ID: 18034334
[TBL] [Abstract][Full Text] [Related]
18. Adrenocorticolytic DDT-metabolites: studies in mink, Mustela vison and otter, Lutra lutra.
Jönsson CJ; Lund BO; Brandt I
Ecotoxicology; 1993 Mar; 2(1):41-53. PubMed ID: 24203118
[TBL] [Abstract][Full Text] [Related]
19. Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line.
Johansson MK; Sanderson JT; Lund BO
Toxicol In Vitro; 2002 Apr; 16(2):113-21. PubMed ID: 11869873
[TBL] [Abstract][Full Text] [Related]
20. Chiral effects in adrenocorticolytic action of o,p'-DDD (mitotane) in human adrenal cells.
Asp V; Cantillana T; Bergman A; Brandt I
Xenobiotica; 2010 Mar; 40(3):177-83. PubMed ID: 20044879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
